07:43 AM EDT, 08/29/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Thursday that it will not proceed with the clinical development of nipocalimab in combination with an anti-tumor necrosis factor alpha therapy in rheumatoid arthritis patients with refractory disease.

The company said the decision was based on the week 12 results of a phase 2a proof-of-concept study, which did not demonstrate enough evidence that the combination therapy had significant added benefit over the anti-tumor necrosis factor alpha therapy alone.

Johnson & Johnson ( JNJ ) said other clinical development programs evaluating nipocalimab in potential indications across rheumatic, rare autoantibody and maternal fetal diseases are ongoing.